UNITY Biotechnology Inc at Cowen Healthcare Conference (Virtual) Transcript
Hi, everyone. Welcome back to Cowen's 41st Healthcare Conference. I am really excited to introduce UNITY Biotech, and Anirvan and Lynne on the management team.
Thanks, Georgi. I'm happy to provide an update on UNITY's platforms and programs. I'm Anirvan Ghosh, CEO of UNITY; and we also have Lynne Sullivan, our CFO, on the call.
Matthew, if you could forward a couple of slides. I'll give an overview of where UNITY is. At UNITY, we're developing therapies to slow, halt or reverse diseases of aging. Our primary interests are in ophthalmology and neurology. In ophthalmology, we're focused on DME, diabetic retinopathy and AMD. In neurology, a number of neurologic indications, including Alzheimer's, FTD and PSP.
The primary mechanism that we are targeting is cellular senescence, and I'll talk a little bit more about that in a minute. But we also have programs that are based on other aging
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |